<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233726</url>
  </required_header>
  <id_info>
    <org_study_id>IR2009</org_study_id>
    <secondary_id>DIABET IR IDI-20080283</secondary_id>
    <nct_id>NCT01233726</nct_id>
  </id_info>
  <brief_title>Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia</brief_title>
  <official_title>Effects of a Complete Diet Rich in Monounsaturated Fatty Acids and Slow Absorption Carbohydrate Administration in Critically Ill Patients With Stress Hyperglycemia. Open Study, Blind Randomised, Multicenter and Controlled.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vegenat, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vegenat, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the beneficial effects of the administration of a
      complete diet rich in monounsaturated fatty acids (MUFA) and slow absorption carbohydrate in
      patients with stress hyperglycemia(T-Diet Plus Diabet IR).

      The main objective of this project is to evaluate blood glucose metabolic control, insulin
      requirements, insulin action resistance, lipid profile and to reduce infectious complications
      on mechanical ventilation ICU (intensive care unit) patients after the administration of a
      complete diet enriched in MUFA and slow absorption carbohydrates, without fructose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enteral formula administration designed for critically ill patients in metabolic stress
      situations, hyperglycemia and insulin resistance, formulated with monounsaturated fatty acids
      (MUFA), slowly absorption carbohydrates, omega-3 series polyunsaturated fatty acids
      (PUFA)enriched in eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA), should be
      associated with an improvement in metabolic control, based on glucose levels reduction, and a
      decrease of insulin resistance infectious complications , mechanical ventilation days, ICU
      and hospital stay. All this against other two high protein conventional specific diets for
      hyperglycaemia patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Biochemical Parameters and Evaluation of Infectious Complications 1</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>The variables recorded related to glycemic control in mg/dL are provided in this table.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Biochemical Parameters and Evaluation of Infectious Complications 2</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>The variables recorded related to administered insulin in IU/day are provided in this table</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Biochemical Parameters and Evaluation of Infectious Complications 3</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>The variables recorded related to number of capillary glycemia measurements are provided in this table</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Biochemical Parameters and Evaluation of Infectious Complications 4</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>The variables recorded related to the number of measurements per patient per day are provided in this table</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Biochemical Parameters and Evaluation of Infectious Complications 5</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>The variables recorded related to Glycemic CV (%) are provided in this table:
Glycemic Coeficient of variation (%) after 28 days in ICU
Glycemic Coeficient of variation (%) after 7 days in ICU.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome: Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.1</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>This table shows the number of capillary glycemia measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.2</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>This table shows the rates of:
Controls analysis on 80-150 mg/dL: optimal level of glycemia rate.
Hypoglycemia (50-80 mg/dL): moderate hypoglycemia rate.
Hypoglycemia (&lt;50 mg/dL): severe hypoglycemia episodes rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Critical Ill Patients Progress During Hospital Stay 1</measure>
    <time_frame>100 days of treatment</time_frame>
    <description>Infectious complication incidence rate per 100 days of treatment are provided in this table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Critical Ill Patients Progress During Hospital Stay 2</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>Number of participants with catheter-associated bloodstream infection, primary bloodstream infection or urinary tract infection are provided in this table</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Critical Ill Patients Progress During Hospital Stay 3</measure>
    <time_frame>28 days post-admission</time_frame>
    <description>The incidence of tracheobronchitis and ventilator-associated pneumonia per 1000 days of mechanical ventilation are provided in this table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Critical Ill Patients Progress During Hospital Stay 4</measure>
    <time_frame>100 days of treatment</time_frame>
    <description>Number of participants with infectious complications is provided in this table.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Critical Illness</condition>
  <condition>Hyperglycemia</condition>
  <condition>Dietary Modification</condition>
  <condition>Metabolic Stress Hyperglycemia</condition>
  <condition>Mechanical Ventilation Complication</condition>
  <arm_group>
    <arm_group_label>T-DIET PLUS DIABET IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISOSOURCE PROTEIN FIBRE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLUCERNA SELECT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>T-Diet plus Diabet IR</intervention_name>
    <description>Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
    <arm_group_label>T-DIET PLUS DIABET IR</arm_group_label>
    <other_name>DIABA HP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ISOSOURCE PROTEIN FIBRE</intervention_name>
    <description>Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
    <arm_group_label>ISOSOURCE PROTEIN FIBRE</arm_group_label>
    <other_name>ISS PROT FIB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLUCERNA SELECT</intervention_name>
    <description>Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
    <arm_group_label>GLUCERNA SELECT</arm_group_label>
    <other_name>GLUC SEL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 admitted to intensive care units (ICU), with mechanical ventilation.

          -  Patients receiving EN (enteral nutrition), for 5 days or more.

          -  ICU stay in 48 hours or less, in the time of study inclusion.

          -  Patients developing hyperglycemia in 48 hours of stay in ICU.

          -  Nutritional support initiation within 48 hours of stay in ICU.

        Exclusion Criteria:

          -  Patients with a life expectancy less than 48 hours.

          -  Patients participating in another study.

          -  Patients with APACHE II (Acute Physiology and Chronic Health Evaluation) less than 10.

          -  Patients with BMI (body mass index) &gt; 40 Kg/m2.

          -  Patients with Type I Diabetes.

          -  Patients on chronic treatment with corticosteroid dose above 1 mg / kg / day of
             methylprednisolone or equivalent.

          -  Pregnant patients.

          -  Patients taking lipid-lowering drugs.

          -  Acute renal failure patients, defined by the following criteria:

               -  Serum creatinine greater than 4 mg / dL with acute rise higher than 0.5 mg / dl /
                  day.

               -  Serum creatinine higher than 3 mg/dL.

               -  Diuresis &lt; 0.3 ml/kg/h during 24 hours.

               -  Anury for 12 hours or more.

          -  Hepatic failure patients, defined by the following parameters:

               -  Serious acute hepatic failure.

               -  Child degrees B-C.

               -  Serum bilirubin higher than 3 mg/dL.

          -  Patients with parenteral nutrition during study inclusion.

          -  Informed consent absence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Mesejo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Carlos Montejo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intensive Care Unit. Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit. Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <results_first_submitted>December 18, 2015</results_first_submitted>
  <results_first_submitted_qc>July 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2016</results_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical illness</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <keyword>Enteral nutrition</keyword>
  <keyword>T-Diet plus Diabet IR</keyword>
  <keyword>Malnutrition</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Metabolic stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study examines whether a high-protein diabetes-specific formula reduces insulin needs, improves glycemic control and reduces ICU-adquired infection in critically ill, hyperglycemic patients on mechanical ventilation (MV)</recruitment_details>
      <pre_assignment_details>The study was performed over the period April 2010 to May 2012. A website was constructed to record data and to randoize patients to each EN formula. Data were collected online using an electronic case report form.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DIABA HP</title>
          <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
DIABA HP group received, 25 kcal / kg /day for 28 days, via gastric or transpyloric.</description>
        </group>
        <group group_id="P2">
          <title>ISOSOURCE PROTEIN FIBRE</title>
          <description>Patients of this group received ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
ISOSOURCE PROTEIN FIBRE group received, 25 kcal / kg / day for 28 days, via gastric or transpyloric.</description>
        </group>
        <group group_id="P3">
          <title>GLUCERNA SELECT</title>
          <description>Patients of this group received GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
GLUCERNA SELECT group will received 25 kcal / kg / day for 28 days, via gastric or transpyloric.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
      <group_list>
        <group group_id="B1">
          <title>DIABA HP</title>
          <description>Patients of this group received new-generation diabetes-specific high-protein formula (Diaba HP®, Vegenat, Badajoz, Spain); as unique nutritional support throughout the day, receiving 25 kcal / kg / day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
DIABA HP group received, 25 kcal / kg/ day for 28 days, via gastric or transpyloric.</description>
        </group>
        <group group_id="B2">
          <title>ISOSOURCE PROTEIN FIBRE</title>
          <description>Patients of this group will received ISOSOURCE PROTEIN FIBRE (Nestlé Health Science, barcelona, Spain) as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
ISOSOURCE PROTEIN FIBRE group received, 25 kcal / kg / day for 28 days, via gastric or transpyloric.</description>
        </group>
        <group group_id="B3">
          <title>GLUCERNA SELECT</title>
          <description>Patients of this group will receive GLUCERNA SELECT (Abbott Nutrition, Madrid, Spain) as unique nutritional support throughout the day, receiving 25 kcal / kg / day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
GLUCERNA SELECT group received 25 kcal / kg / day for 28 days, via gastric or transpyloric.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="43" upper_limit="70"/>
                    <measurement group_id="B2" value="60" lower_limit="45" upper_limit="71"/>
                    <measurement group_id="B3" value="58" lower_limit="46" upper_limit="68"/>
                    <measurement group_id="B4" value="58" lower_limit="43" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="24" upper_limit="29"/>
                    <measurement group_id="B2" value="26" lower_limit="24" upper_limit="28"/>
                    <measurement group_id="B3" value="26" lower_limit="24" upper_limit="27"/>
                    <measurement group_id="B4" value="26" lower_limit="24" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APACHE II</title>
          <description>Acute Physiology and Chronic Health Evaluation II
Scale: 0 to 71: based on several measures: at higher score, more severe illness and greater risk of death.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" lower_limit="14" upper_limit="23"/>
                    <measurement group_id="B2" value="19" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="B3" value="19" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="B4" value="19" lower_limit="14" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SOFA score</title>
          <description>Sepsis-related Organ Failure Assessment score.
Score:
0-6: 10% of mortality; 7-9: 15-20% of mortality; 10-12: 40-50% of mortality; 13-14: 50-60 % of mortality; 15: &gt;80% of mortality; 16-24: &gt;90% of mortality.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="6" upper_limit="14"/>
                    <measurement group_id="B2" value="7" lower_limit="5" upper_limit="12"/>
                    <measurement group_id="B3" value="7" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="B4" value="8" lower_limit="4" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Calorie requirements</title>
          <units>kcal/day</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1690.4" spread="384.9"/>
                    <measurement group_id="B2" value="1707.1" spread="275.4"/>
                    <measurement group_id="B3" value="1728.2" spread="309.2"/>
                    <measurement group_id="B4" value="1708.6" spread="323.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Start of EN</title>
          <description>Start of Enteral Nutrition: elapsed time from admission to start enteral nutrition</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.4" lower_limit="18.1" upper_limit="27.2"/>
                    <measurement group_id="B2" value="25.1" lower_limit="19.6" upper_limit="26.2"/>
                    <measurement group_id="B3" value="26.7" lower_limit="21.3" upper_limit="28"/>
                    <measurement group_id="B4" value="25.1" lower_limit="18.1" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Noninsulin-dependent diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentaje of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.34" spread="1.38"/>
                    <measurement group_id="B2" value="5.76" spread="0.95"/>
                    <measurement group_id="B3" value="6.07" spread="1.39"/>
                    <measurement group_id="B4" value="6.1" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Capillary glucose level</title>
          <description>Measured after fasting and without insulin infusion for at least 8 hours</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148.8" spread="38.8"/>
                    <measurement group_id="B2" value="149.9" spread="38.9"/>
                    <measurement group_id="B3" value="151.5" spread="39.23"/>
                    <measurement group_id="B4" value="150" spread="38.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma glucose level</title>
          <description>Measured after fasting and without insulin infusion for at least 8 hours</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152.1" spread="54.6"/>
                    <measurement group_id="B2" value="147.01" spread="55.93"/>
                    <measurement group_id="B3" value="152.1" spread="57.12"/>
                    <measurement group_id="B4" value="150.4" spread="55.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulinemia</title>
          <description>Measured after fasting and without insulin infusion for at least 8 hours</description>
          <units>microU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.59" spread="36.06"/>
                    <measurement group_id="B2" value="17.39" spread="23.77"/>
                    <measurement group_id="B3" value="19.15" spread="20.5"/>
                    <measurement group_id="B4" value="19.38" spread="26.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-peptide</title>
          <description>Measured after fasting and without insulin infusion for at least 8 hours</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.61" spread="3.24"/>
                    <measurement group_id="B2" value="4.49" spread="2.92"/>
                    <measurement group_id="B3" value="4.27" spread="3.67"/>
                    <measurement group_id="B4" value="4.46" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA2 IR</title>
          <description>HOMA 2: Homeostasis Model Assessment IR: Insulin Resistance. Homeostatic model assessment (HOMA) is a method for assessing β-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide concentrations.
The HOMA model compares favorably with other models and has the advantage of requiring only a single plasma sample assayed for insulin and glucose. Higher values represent higher insulinemia.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.94" spread="4.19"/>
                    <measurement group_id="B2" value="2.48" spread="2.76"/>
                    <measurement group_id="B3" value="3.38" spread="2.37"/>
                    <measurement group_id="B4" value="2.93" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA2 %B</title>
          <description>HOMA 2: Homeostasis Model Assessment B: Beta cell function.
Homeostatic model assessment (HOMA) is a method for assessing β-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide concentrations.</description>
          <units>% of beta cell function</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102.6" spread="57.81"/>
                    <measurement group_id="B2" value="110.5" spread="74.34"/>
                    <measurement group_id="B3" value="96.55" spread="85.09"/>
                    <measurement group_id="B4" value="103.21" spread="72.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA2 %S</title>
          <description>HOMA2: Homeostasis Model Assessment S: Insulin Sensitivity</description>
          <units>% of insulin sensitivity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.12" spread="75.2"/>
                    <measurement group_id="B2" value="69.6" spread="48.7"/>
                    <measurement group_id="B3" value="68.09" spread="66.9"/>
                    <measurement group_id="B4" value="72.27" spread="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infection</title>
          <description>Number of patients with infection from any source</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnostic group: Medical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnostic group: Trauma</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnostic group: Surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 1</title>
        <description>The variables recorded related to glycemic control in mg/dL are provided in this table.</description>
        <time_frame>28 days post-admission</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>Diaba HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group Diaba HP received, 25 kcal / kg /day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
Group Isosource protein fibre will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 1</title>
          <description>The variables recorded related to glycemic control in mg/dL are provided in this table.</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma glucose level (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.6" spread="39.1"/>
                    <measurement group_id="O2" value="146.1" spread="49.9"/>
                    <measurement group_id="O3" value="143.9" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capillary glucose level (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.1" spread="45.8"/>
                    <measurement group_id="O2" value="155.3" spread="63.6"/>
                    <measurement group_id="O3" value="150.1" spread="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean capillary glycemia on ICU day 1 (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.5" spread="40.2"/>
                    <measurement group_id="O2" value="160" spread="55.5"/>
                    <measurement group_id="O3" value="145.6" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak glucose level (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.3" spread="52"/>
                    <measurement group_id="O2" value="193.6" spread="74.6"/>
                    <measurement group_id="O3" value="191.3" spread="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycemic variability SD (mg/dL) (ICU days 1-28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="18.4"/>
                    <measurement group_id="O2" value="49.1" spread="21.5"/>
                    <measurement group_id="O3" value="41.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycemic variability SD (mg/dL) (ICU days 1-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="4.9"/>
                    <measurement group_id="O2" value="68.5" spread="13.5"/>
                    <measurement group_id="O3" value="42.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 2</title>
        <description>The variables recorded related to administered insulin in IU/day are provided in this table</description>
        <time_frame>28 days post-admission</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>Diaba HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group Diaba HP received, 25 kcal / kg /day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
Group Isosource protein fibre will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 2</title>
          <description>The variables recorded related to administered insulin in IU/day are provided in this table</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>IU/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="13.1"/>
                    <measurement group_id="O2" value="23.7" spread="40.1"/>
                    <measurement group_id="O3" value="20.3" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 3</title>
        <description>The variables recorded related to number of capillary glycemia measurements are provided in this table</description>
        <time_frame>28 days post-admission</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>Diaba HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group Diaba HP received, 25 kcal / kg /day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
Group Isosource protein fibre will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 3</title>
          <description>The variables recorded related to number of capillary glycemia measurements are provided in this table</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>Capillary glycemia measurements</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3605"/>
                    <measurement group_id="O2" value="3523"/>
                    <measurement group_id="O3" value="3557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 4</title>
        <description>The variables recorded related to the number of measurements per patient per day are provided in this table</description>
        <time_frame>28 days post-admission</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>Diaba HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group Diaba HP received, 25 kcal / kg /day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
Group Isosource protein fibre will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 4</title>
          <description>The variables recorded related to the number of measurements per patient per day are provided in this table</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>Measurements per patient/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="3.4"/>
                    <measurement group_id="O2" value="5.81" spread="3.2"/>
                    <measurement group_id="O3" value="5.46" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 5</title>
        <description>The variables recorded related to Glycemic CV (%) are provided in this table:
Glycemic Coeficient of variation (%) after 28 days in ICU
Glycemic Coeficient of variation (%) after 7 days in ICU.</description>
        <time_frame>28 days post-admission</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>Diaba HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group Diaba HP received, 25 kcal / kg /day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
Group Isosource protein fibre will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 5</title>
          <description>The variables recorded related to Glycemic CV (%) are provided in this table:
Glycemic Coeficient of variation (%) after 28 days in ICU
Glycemic Coeficient of variation (%) after 7 days in ICU.</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>percentage of Glycemic CV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glycemic CV (%) (ICU days 1-28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" spread="5.8"/>
                    <measurement group_id="O2" value="32.4" spread="11.2"/>
                    <measurement group_id="O3" value="27.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycemic CV (%) (ICU days 1-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="1.9"/>
                    <measurement group_id="O2" value="42.6" spread="8.2"/>
                    <measurement group_id="O3" value="28.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome: Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.1</title>
        <description>This table shows the number of capillary glycemia measurements</description>
        <time_frame>28 days post-admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diaba HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group Diaba HP received, 25 kcal / kg /day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
Group Isosource protein fibre will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome: Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.1</title>
          <description>This table shows the number of capillary glycemia measurements</description>
          <units>number of capillary glycemia measurement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3605"/>
                    <measurement group_id="O2" value="3523"/>
                    <measurement group_id="O3" value="3557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.2</title>
        <description>This table shows the rates of:
Controls analysis on 80-150 mg/dL: optimal level of glycemia rate.
Hypoglycemia (50-80 mg/dL): moderate hypoglycemia rate.
Hypoglycemia (&lt;50 mg/dL): severe hypoglycemia episodes rate.</description>
        <time_frame>28 days post-admission</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>Diaba HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group Diaba HP received, 25 kcal / kg /day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
Group Isosource protein fibre will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.2</title>
          <description>This table shows the rates of:
Controls analysis on 80-150 mg/dL: optimal level of glycemia rate.
Hypoglycemia (50-80 mg/dL): moderate hypoglycemia rate.
Hypoglycemia (&lt;50 mg/dL): severe hypoglycemia episodes rate.</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>% of capillary glycemia measurements</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controls on 80-150 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="57.6"/>
                    <measurement group_id="O3" value="59.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia (50-80 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48"/>
                    <measurement group_id="O2" value="3.63"/>
                    <measurement group_id="O3" value="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia (&lt;50 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.11"/>
                    <measurement group_id="O3" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Critical Ill Patients Progress During Hospital Stay 1</title>
        <description>Infectious complication incidence rate per 100 days of treatment are provided in this table.</description>
        <time_frame>100 days of treatment</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>DIABA HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
DIABA HP GROUP received, 25 kcal / kg /day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
ISOSOURCE PROTEIN FIBRE group will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
GLUCERNA SELECT group will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Critical Ill Patients Progress During Hospital Stay 1</title>
          <description>Infectious complication incidence rate per 100 days of treatment are provided in this table.</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>percentage of patients with infection</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Critical Ill Patients Progress During Hospital Stay 2</title>
        <description>Number of participants with catheter-associated bloodstream infection, primary bloodstream infection or urinary tract infection are provided in this table</description>
        <time_frame>28 days post-admission</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>DIABA HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
DIABA HP GROUP received, 25 kcal / kg /day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
ISOSOURCE PROTEIN FIBRE group will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
GLUCERNA SELECT group will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Critical Ill Patients Progress During Hospital Stay 2</title>
          <description>Number of participants with catheter-associated bloodstream infection, primary bloodstream infection or urinary tract infection are provided in this table</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Catether-related bloodstream infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary bloodstream infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Critical Ill Patients Progress During Hospital Stay 3</title>
        <description>The incidence of tracheobronchitis and ventilator-associated pneumonia per 1000 days of mechanical ventilation are provided in this table.</description>
        <time_frame>28 days post-admission</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>DIABA HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
DIABA HP GROUP received, 25 kcal / kg /day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
ISOSOURCE PROTEIN FIBRE group will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
GLUCERNA SELECT group will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Critical Ill Patients Progress During Hospital Stay 3</title>
          <description>The incidence of tracheobronchitis and ventilator-associated pneumonia per 1000 days of mechanical ventilation are provided in this table.</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>number of new cases per 1000 days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tracheobonchitis incidence rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventilator-associated pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Critical Ill Patients Progress During Hospital Stay 4</title>
        <description>Number of participants with infectious complications is provided in this table.</description>
        <time_frame>100 days of treatment</time_frame>
        <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
        <group_list>
          <group group_id="O1">
            <title>Diaba HP</title>
            <description>Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group Diaba HP received, 25 kcal / kg /day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>ISOSOURCE PROTEIN FIBRE</title>
            <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
Group Isosource protein fibre will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
          <group group_id="O3">
            <title>GLUCERNA SELECT</title>
            <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Critical Ill Patients Progress During Hospital Stay 4</title>
          <description>Number of participants with infectious complications is provided in this table.</description>
          <population>Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose &gt;126 mg/dL after fasting or&gt;200 mg/dL otherwise) in the first 48 h of ICU admission.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All participants were followed at the ICU for a maximum of 28 days.</time_frame>
      <desc>No adverse effects have been observed and/or registered related with the products intake during the clinical trial period. Data provided in outcome measure are related with the individual patology of each patient, not with the product intake (enteral nutrition intake).</desc>
      <group_list>
        <group group_id="E1">
          <title>DIABA HP</title>
          <description>Patients of this group received Diaba HP® as unique nutritional support throughout the day, receiving 25 kcal / kg / day (from the first 48 hours after checking tolerance) via gastric or transpyloric
Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
DIABA HP group received, 25 kcal / kg /day for 28 days, via gastric or transpyloric.</description>
        </group>
        <group group_id="E2">
          <title>ISOSOURCE PROTEIN FIBRE</title>
          <description>Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg / day (from the first 48 hours after checking tolerance) via gastric or transpyloric
ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture.
ISOSOURCE PROTEIN FIBRE group received, 25 kcal / kg / day for 28 days, via gastric or transpyloric.</description>
        </group>
        <group group_id="E3">
          <title>GLUCERNA SELECT</title>
          <description>Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg/ day (from the first 48 hours after checking tolerance) via gastric or transpyloric
GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
GLUCERNA SELECT group will receive 25 kcal / kg / day for 28 days, via gastric or transpyloric.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No overall limitations and caveats have been observed and/or registered related with the products intake during the clinical trial period.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alfonso Mesejo</name_or_title>
      <organization>Intensive Care Unit, Hospital Clínico Universitario</organization>
      <phone>961 97 35 00</phone>
      <email>mesejo_alf@gva.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

